HeartMate 3生存风险评分在大型左心室辅助装置中心的验证
本研究为单中心回顾性研究,纳入2017年9月至2022年8月共181例HeartMate 3左心室辅助装置植入患者,计算HM3生存风险评分并分析1年及2年生存率。
要点
- 未调整HM3评分与植入后生存相关(HR 2.20),调整后非独立预测因子。
- 原始三分位分层的区分能力未能得到验证。
核心结论
- 未调整HM3评分与植入后生存相关,但调整缺血性病因和严重糖尿病后非独立预测因子。
- HM3评分使用二分界值可识别高生存组,但原始三分位分层未显示区分能力。
研究设计与样本
- 单中心回顾性研究,纳入2017年9月至2022年8月共181例HeartMate 3左心室辅助装置患者。
- 计算HM3生存风险评分,进行1年和2年Kaplan-Meier生存分析及Cox回归。
主要发现
- 中位年龄62岁,男性83%,INTERMACS Profile 1占26%,平均HM3评分2.66±0.66。
- 2年生存率:高生存组93.5%±3.2%,平均生存组81.6%±7.4%,低生存组82.0%±6.6%。
关键数值与推荐
- HM3评分三分位分层:高、平均、低生存组2年生存率分别为93.5%±3.2%、81.6%±7.4%、82.0%±6.6%。
临床怎么用
- 未调整HM3评分可用于评估植入后生存风险,但需考虑缺血性病因和严重糖尿病的影响。
- 二分界值可能有助于识别高生存患者,原始三分位分层的临床区分能力有限。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The HeartMate 3 survival risk score was recently validated in the Multicenter study Of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 to predict patient-specific survival in HeartMate 3 left ventricular assist device candidates. The HeartMate 3 survival risk score stratifies individuals into tertiles according to survival probability. METHODS: We performed a single-center retrospective review of all HeartMate 3 left ventricular assist device recipients between September 2017 and August 2022. Baseline characteristics were collected from the electronic medical records. HeartMate 3 survival risk scores were calculated for all eligible patients. One- and 2-year Kaplan-Meier survival analyses were conducted. A univariate and multivariable Cox regression model was used to identify predictors. RESULTS: A total of 181 patients were included in this final analysis. The median age was 62 years, 83% were male, and 26% were Interagency Registry for Mechanically Assisted Circulatory Support Profile 1. The mean HeartMate 3 survival risk score for the entire cohort was 2.66 ± 0.66. Two-year survivals in the high, average, and low survival groups were 93.5% ± 3.2%, 81.6% ± 7.4%, and 82.0% ± 6.6%, respectively. As a continuous variable, the unadjusted HeartMate 3 survival risk score was a significant predictor of mortality (hazard ratio, 2.20; 95% CI, 1.08-4.45; P = .029). The areas under the curve were 0.70 and 0.66 at 1 and 2 years, respectively. We were unable to demonstrate the discriminatory ability of the HeartMate 3 survival risk score using the original stratification, but we found significantly increased survival in the high survival group using a binary cutoff (hazard ratio, 4.8; 95% CI, 1.01-20.9; P = .038). CONCLUSIONS: The unadjusted HeartMate 3 survival risk score was associated with postimplant survival in patients outside of the Multicenter study Of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 but did not remain an independent predictor after adjusting for ischemic etiology and severe diabetes. The HeartMate 3 survival risk score was able to identify patients at high survival using a binary cutoff, but we were unable to demonstrate its discriminatory ability among the previously published risk tertiles.
引用
- Moeller CM, Rubinstein G, Oren D, et al. Validation of the HeartMate 3 survival risk score in a large left ventricular assist device center. J Thorac Cardiovasc Surg. 2024. PMID: 39023496. doi:10.1016/j.jtcvs.2024.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。